Researchers in China have achieved what many believed couldn't be done: they've created viable, healthy mice using genetic ...

EditCo Bio, a leader in cutting-edge genetic engineering and cellular model solutions, today announced the launch of XDel Knockout Cells, an innovative product designed to revolutionize the field of ...

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

Scientists in China have manipulated embryonic stem cells to create laboratory mice with two male parents that managed to ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

The first mouse with two biological fathers has survived until adulthood, a new study has revealed. Researchers from the ...

DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a biotechnology firm specializing in bioengineered human tissues with a current market capitalization of $580 million, and Pluristyx, Inc., a provider of ...

The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™) products for cancer and autoimmune disease, today ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue ...

DURHAM, N.C.and SEATTLE, Jan. 28, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...

In trials at University College London Hospitals (UCLH), an ASO is being used to target the mutated gene that results in the ...